EHMT2 and plasma cell myeloma: A recent study reported high expression of G9a in various cancers, such as prostate/colon/lung cancers, multiple myeloma, and lymphocytic leukemia, indicating that G9a inhibitors might suppress cancer proliferation (41, 77).